Axsome Therapeutics presented new clinical data for major depressive disorder and Alzheimer's disease agitation at Psych Congress 2026. The company showcased 10 posters featuring new findings and encore presentations from its psychiatry and neurology portfolios. This data will inform future clinical practices and upcoming regulatory discussions.
The presentations support Axsome’s strategy to build a diversified central nervous system portfolio and reduce single-product reliance. Management aims to demonstrate the utility of assets like Auvelity across multiple high-need indications.
Axsome currently manages five ongoing Phase 3 programs. The company is also awaiting a regulatory decision for its narcolepsy treatment candidate.